Kornimate/medical-research-clean huggingface dataset:
exploring nursing students' ability to create artificial intelligence-enhanced patient education materials on infection care

Conditions: Nursing Students; Artificial Intelligence (AI); Patient Education Materials; Randomized Controlled Trial

Summary: the purpose of this study is to explore the ability of nursing students to create artificial intelligence-supported patient education materials regarding infection care. this study will be conducted as a randomized controlled experimental study. data of the study will be collected with the descriptive characteristics form, patient education information form and patient education materials assessment tool (hemda).


Eligibility criteria:
inclusion criteria: * to take basic principles and practices in nursing-ii for the first time * not to work as a nurse in a hospital or any health institution exclusion criteria: * having previously prepared patient education materials; * retaking the basic principles and practices in nursing-ii course * having difficulty speaking and understanding turkish; * not attending class

Keywords: nursing students artificial intelligence (ai) patient education materials randomized controlled trial
feasibility study of supine breast mri : comparison with prone mri and comfort assessment

Conditions: Breast Diseases

Summary: the aim of the present study was to determine the prone-to-supine displacement of breast lesions using preoperative prone mri and supine second-look ultrasound data


Eligibility criteria:
inclusion criteria: * the inclusion criteria were being a woman with breast lesions whose assessment involved breast mri and ultrasound at our institution. there were no exclusion criteria. exclusion criteria: -

Keywords: mri breast
vending machine naloxone distribution for your community (vendy)

Conditions: Harm Reduction; Naloxone; Opioid Overdose

Summary: vending machines are an innovative strategy shown to increase access to naloxone, a medication used to reverse opioid overdose. the aim of this proposal is to study the reach of a community-initiated, stakeholder engaged adaptation of naloxone distribution, vending machine naloxone distribution for your community (vendy) program.

this pilot assessment of the vendy program will take place in 3 communities. each community will have a machine (vending or kiosks) in which naloxone will be distributed for free to community members. our preliminary work identified the locations desired by community members who use illegal drugs for machine placement. the pilot test test will include evaluation of the reach (naloxone distribution), adoption (% of sites and staff implementing), and implementation (fidelity to restocking and maintenance protocol) of vendy in each community.

Eligibility criteria:
inclusion criteria: * any person in the community who desires to obtain naloxone will be able to use the machines exclusion criteria: * inability to enter a code on a vending machine or open a kiosk.
regenerative endodontics in mature permanent teeth

Conditions: Regenerative Endodontics

Summary: this study was designed to compare the clinical and radiographic success of reps after using blood clot scaffold in non-vital mature permanent teeth with or without photobiomodultion therapy


Eligibility criteria:
inclusion criteria: * patients free from any systemic diseases or genetic disorders. * children aged 9-13 years old of both sexes. * traumatically or cariously exposed single rooted mature permanent teeth which may be asymptomatic or manifested with dull ache pain, or spontaneous unprovoked toothache. * non-vital single rooted mature permanent teeth that indicated for endodontic treatment * swelling close to involved tooth accompanied with or without fistula. * negative response to cold \& electrical pulp test. * informed consent. exclusion criteria: * unrestorable teeth, or that need post and core for the final restoration. * immature permanent teeth. * known allergy, sensitivity to ciprofloxacin, metronidazol. * uncooperativeness of child and/or parents or caregiver's behavior. * presence of calcific metamorphosis inside root canals.
leo 90100 aerosol foam compared to calcipotriol plus betamethasone dipropionate gel in subjects with psoriasis vulgaris

Conditions: Psoriasis Vulgaris

Summary: the purpose is to compare the efficacy of treatment with leo 90100 at week 4 to that of calcipotriol plus betamethasone dipropionate (bdp) gel at week 8 in subjects with psoriasis vulgaris


Eligibility criteria:
inclusion criteria: * age 18 years or above * psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2-30% of the body surface area (bsa) * a physician's global assessment of disease severity (pga) of at least mild on trunk and limbs * a modified psoriasis area severity index (pasi) score of at least 2 on the trunk and limbs. exclusion criteria: * current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis * systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation: * etanercept - within 4 weeks prior to randomisation * adalimumab, infliximab - within 8 weeks prior to randomisation * ustekinumab - within 16 weeks prior to randomisation * other products - within 4 weeks/5 half-lives prior to randomisation (whichever is longer) * systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants within 4 weeks prior to randomisation) * subjects who have received treatment with any non-marketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation. * psoralen combined with ultraviolet a (puva) therapy within 4 weeks prior to randomisation * ultraviolet b (uvb) therapy within 2 weeks prior to randomisation * topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within 2 weeks prior to randomisation * topical treatment on the face, scalp and skin folds with corticosteroids, vitamin d analogues or prescription shampoos within 2 weeks prior to randomisation * females who are pregnant, wishing to become pregnant during the trial or are breastfeeding
reducing cardiovascular disease (cvd) risk in hiv on antiretroviral therapy over 12 months

Conditions: HIV-1 Infection; Cardiovascular Disease

Summary: this is a cohort study which follows two groups of participants over a 12 months period. one group will access a team approach to care with the aim of reducing their cardiovascular disease (cvd) risks from a team of doctors, nurses and health care professionals. the other group will continue to access standard care from their treating doctor. both groups will have cvd risk score evaluated after a 12 month period. the team care approach will involve specific tests to measure cvd risk as well as smoking cessation, exercise and dietary advice and support, including monitoring such as blood pressure and cholesterol levels


Eligibility criteria:
intervention study intervention arm inclusion criteria: 1. documented hiv-1 infection 2. age 50 years or older 3. stable on art ≥ 3/12 4. undetectable plasma hiv rna (\< 50 copies/ml) 5. moderate or high framingham cvd risk score 6. life expectancy \> 12 months 7. regular patient under care of non-director physician 8. willing to adhere to pharmacological cvd risk reduction intervention 9. willing to participate in lifestyle change advice intervention exclusion criteria for intervention study 1. life expectancy \< 1yr 2. unable to undertake exercise 3. drug dependency 4. cognitive impairment affecting ability to participate in study 5. pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcg laboratory test (\> 5mi u/ml) 6. women of childbearing potential who are unwilling to use reliable contraception for the duration of the study inclusion criteria for intervention study control arm (group 2) 1. documented hiv-1 infection 2. age 50 years or older 3. stable on art ≥3/12 4. undetectable plasma hiv rna (\<50 copies/ml) 5. moderate or high framingham risk score (\>10%) 6. life expectancy \> 12 months 7. regular patient under care of non-director physician

Keywords: cardiovascular disease hiv antiretroviral treatment team interventions framingham risk score
safety, tolerability and pharmacokinetics of aerosolized amikacin in intubated and mechanically-ventilated patients with nosocomial pneumonia

Conditions: Pneumonia

Summary: this study is to understand how the inhaled form of amikacin is spread throughout the human body and how it is eliminated from the body and to make sure that giving an inhaled form of amikacin to patients is safe and well tolerated


Eligibility criteria:
inclusion criteria: * male or female subjects with confirmed pneumonia, defined as the presence of a new progressive infiltrate(s) on chest radiograph and the presence of gram-negative organism by either culture or gram stain of respiratory secretions. the subject must be intubated and mechanically ventilated and expected to remain so for at least 3 days after the start of study treatment. subjects with a tracheostomy were also eligible. exclusion criteria: * subjects with compromised or suppressed immune systems, severe hypoxemia, neutropenia, serum creatinine \> 2mg/dl and chronic liver disease * had primary lung cancer or another malignancy metastatic to the lungs * were known or suspected to have active tuberculosis, cystic fibrosis, acquired immunodeficiency syndrome, or pneumocystis carinii pneumonia * were receiving immunosuppressive therapy, defined as chronic treatment with known immunosuppressant medications * had a body mass index of ≥30 kg/m2 * had burns \>40% of total body surface area * had known local or systemic hypersensitivity to amikacin or aminoglycosides * had a diagnosis of end-stage renal failure or were currently on dialysis treatment * had a serum albumin level \<2 g/dl at screening * used amikacin by any route within 7 days before the start of study treatment * had a presence of any concomitant condition that, in the opinion of the investigator, would preclude completion of study evaluations or make it unlikely that the contemplated course of therapy and follow-up could be completed * had known respiratory colonization with amikacin-resistant gram-negative rods

Keywords: pneumonia gram-negative bacteria
opioid reduction toolkit reduces opioids prescribed and consumed

Conditions: Opioid Abuse; Opioid Misuse; Pain

Summary: investigators studied a baseline population of patients receiving pancreatectomies at their institution and determined how many opioid pills each patient was prescribed and how many they took. based on this data they created a toolkit to provide to prescribers to give patients a modified number of pills. the amount prescribed and consumed was measured after intervention.

a single academic surgical department reviewed opioid treatment patterns for patients undergoing common procedures, including open pancreatectomy, and an opioid reduction toolkit using the data collected was created. providers were educated on the use of the toolkit and it was implemented as a standard of practice. data were collected on pancreatectomy patients via telephone interview (performed at 2 weeks post-op) and by reviewing the state prescription drug monitoring program. outcome variables included morphine milliequivalents (mme) of pills prescribed, mme of pills consumed, number of patients aware of proper unused pill disposal, number of patients requesting refills, and pain scores. categorical and continuous outcomes were compared within and between groups.

Eligibility criteria:
inclusion criteria: * age \> 18 * being scheduled for an outpatient elective pancreatectomy exclusion criteria: * urgent/emergent status * concomitant procedure being performed at time of pancreatectomy
the safety of tenofovir disoproxil fumarate taken with other anti-hiv drugs to treat hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir df) in combination with other anti-hiv drugs in patients who have participated in other tenofovir df studies (gs-98-902 or gs-99-907), are able to tolerate the drug at different doses, and may benefit from having tenofovir df treatment.

patients take tenofovir df in combination with other antiretrovirals.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * have completed another study on tenofovir df without toxicity. * are willing to use intrauterine or effective barrier methods of birth control, both men and women, during the study and for 30 days following tenofovir df treatment. exclusion criteria patients will not be eligible for this study if they: * are taking drugs that may damage the kidney (nephrotoxic) including aminoglycoside antibiotics, amphotericin b, cidofovir, cisplatin, foscarnet, iv pentamidine, vancomycin, and oral or iv ganciclovir. * are taking agents that affect kidney function, such as probenecid. * are receiving systemic chemotherapy. * are taking systemic corticosteroids. * are taking experimental drugs except those that are approved by gilead. * are currently participating in the gs-99-908 or gs-00-912 (expanded access) studies. * are pregnant or breast-feeding.

Keywords: hiv-1 drug therapy, combination reverse transcriptase inhibitors anti-hiv agents 9-(2-phosphonylmethoxypropyl)adenine
telemedicine for patients with an hybrid closed loop system

Conditions: Diabetes Mellitus, Type 1

Summary: the primary objective is to assess the impact on quality of life after a follow-up program using a telemedicine platform designed for patients with dm1 treated with an hybrid closed loop insulin infusion system. open-label, randomized 1:1 controlled clinical trial during 12 months.


Eligibility criteria:
inclusion criteria: * diagnostic criteria for dm1 according to ada * they must have access to the technology that allows monitoring (mobile phone and / or computer as well as having an internet connection) * acceptance of participation in the study and signing of the informed consent exclusion criteria: * gestation * institutionalization, serious or terminal illness or renal replacement therapy. * inability to undertake the training and / or acquire the degree of knowledge to use the telemedicine platform. * refusal to participate in the study or to sign the informed consent
effects of dynamic compression garments in children with cp

Conditions: Cerebral Palsy

Summary: in recent years, it is seen that dynamic compression garments are used to increase body stability and to provide tone regulation. dynamic compression garments are used to apply pressure to specific muscles or muscle groups. different studies have drawn attention to the effect of dynamic compression garments on postural control and proximal stability. researchers observed that upper extremity functions and fine motor skills improved with the use of clothing, and they associated this with improved proximal stability. in light of this information, the aim of this study is; to investigate the effects of dynamic compression garments applied in addition to traditional treatment on posture, trunk control, and upper extremity functions during sitting in children with hemiparetic cp.

cerebral palsy (cp) is a group of permanent neurodevelopmental disorders in the development of movement and posture, non-progressive, resulting in activity limitations, resulting from an injury to the developing brain. children with cp who have problems in sensorimotor coordination due to decreased muscle strength and impaired sensory processing experience postural control problems. in hemiparetic cp, deterioration in the upper extremities affects children's daily living activities such as eating, dressing, undressing, combing hair, brushing teeth, self-care skills, functional independence, and quality of life. since the trunk plays a very important role in postural control and extremity functions, providing trunk stability and thus effective use of the extremities is one of the important goals of physiotherapy.

Eligibility criteria:
inclusion criteria: 1. being diagnosed with congenital spastic hemiparetic cerebral palsy, 2. to be between the ages of 4-18 3. to be at the level of i, ii or iii according to the manual ability classification system 4. having sufficient communication skills 5. the willingness of the family and the child to be included in the study exclusion criteria: 1. the family's refusal to participate in the study 2. botulinum toxin application to the upper extremity or having undergone upper extremity surgery in the last 6 months 3. having behavioral and communication problems that hinder the practices to be carried out within the scope of the study 4. having an epileptic seizure

Keywords: cerebral palsy dynamic compression postural control trunk control upper extremity function
a study of indoximod or placebo plus pembrolizumab or nivolumab for subjects with unresectable or metastatic melanoma

Conditions: Melanoma

Summary: this is an adaptive clinical trial that includes a dose escalation phase followed by a randomized controlled phase 3 trial. the purpose of the dose escalation phase is to establish the phase 3 dose of indoximod in combination with pembrolizumab or nivolumab in subjects with unresectable or metastatic melanoma and evaluate pk. subsequently the efficacy, safety and tolerability of indoximod plus pembrolizumab or nivolumab versus placebo plus pembrolizumab or nivolumab will be studied in subjects with unresectable or metastatic melanoma in the phase 3 portion of the trial. the phase 3 study will not proceed per sponsor decision.


Eligibility criteria:
inclusion criteria: * have histologically- or cytologically-confirmed unresectable stage iii or stage iv melanoma not amenable to local therapy * at least one radiologically measurable lesion as per recist 1.1 * have documentation of v600-activating braf mutation status or consent to braf v600 mutation testing during the screening period. * ecog performance status 0 or 1 * ability to ingest oral medications exclusion criteria: * has ocular melanoma * has received prior systemic treatment for unresectable or metastatic melanoma (except braf directed therapy). * has received prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or ido1 inhibitor or any other antibody or drug specifically targeting checkpoint pathways other than anti-ctla-4 which is permitted in the adjuvant setting. * has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer) * has received prior radiotherapy within 2 weeks of therapy. * is pregnant or breast-feeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment. * patients who have active, chronic, or on active treatment for hep b or hep c are excluded.

Keywords: melanoma, metastaic melanoma
does intravitreal injection of triamcinolone acetonide impairs the adrenal function

Conditions: Secondary Adrenal Insufficiency

Summary: the use of intravitreal corticosteroids in the management ocular inflammatory diseases has recently gained widespread acceptance. the purpose of this study is to determine if the use of intravitreal triamcinolone is associated with suppression of endogenous cortisol production, as generally admitted for patients treated with oral or parenteral corticosteroid therapy.

the normalcy of hypothalamic- pituitary- adrenal axis (hpa axis) of enrolled subjects will will be assessed before intravitreal injection of 4mg of triamcinolone and again after one day, one week and two weeks. patients with abnormal hpa axis will be re-tested after four weeks and later until the hpa axis function return to normal. the hpa axis will be assessed with low dose (1mcg) intravenous corticotropin(acth) stimulation test, in which cortisol levels will be sampled before , 30 minutes and 60 minutes after 1mcg acth iv injection.

Eligibility criteria:
inclusion criteria: * patients receiving intravitreous injection of triamcinolone 4mg exclusion criteria: * patients receiving steroids in any form, except by intravitreous administration
a study to evaluate the safety and the activity of s095029 as part of combination therapy in advanced gastroesophageal junction/gastric cancers.

Conditions: MSI-H/dMMR Gastroesophageal-junction Cancer; MSI-H/dMMR Gastric Cancer

Summary: this study will investigate the safety, tolerability, and antitumor activity of s095029 (anti-nkg2a antibody) in combination with pembrolizumab in in microsatellite instability-high/defective mismatch repair (msi-h/dmmr) locally advanced unresectable or metastatic gastric /gej adenocarcinomas.

this phase 1b/2 study will be conducted in two parts; a safety lead-in part (phase 1b) to identify the rp2d of s095029 in combination with pembrolizumab and an expansion part (phase 2) to evaluate anti-tumor activity and safety in participants with locally advanced unresectable or metastatic msi-h/dmmr gastric /gej adenocarcinomas.

Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of locally advanced and unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma * participants' tumor must have an msi-h/dmmr status according to institutional guidelines and/or according to the college of american pathologists, determined at any time prior to enrolment. exclusion criteria: * has received more than one previous line of treatment in the locally advanced and unresectable or metastatic setting. * has received prior therapy with any checkpoint inhibitor (anti-pd-1, anti-programmed cell death ligand 1 (pdl1), anti-ctla4). * participants who have received prior systemic anti-cancer therapy including investigational agents within 4 weeks (shorter interval, at least 5 half-lives, for kinase inhibitors or other short half-life drugs) prior to first study treatment. * prior radiotherapy if completed less than 2 weeks before first study treatment * major surgery less than 4 weeks prior to the first study treatment or participants who have not recovered from the side effects of the surgery.

Keywords: anti-nkg2a s095029 pembrolizumab msi-h/dmmr gastric cancer gastroesophageal-junction cancer
neuroscience pain education in patients with chronic low back pain

Conditions: Chronic Low Back Pain; Manual Therapy; Neuroscience Pain Education

Summary: the cognitive educational strategies such as neuroscience pain education, has been a popular and promising technique for treatment patients with chronic pain. however, there are not sufficient randomized controlled and blinded studies to explore clinical effectiveness of these techniques. therefore, the aim of this study was determining the short- and mid-term effects of neuroscience pain education combined with manual therapy and home exercise on pain level, disability, and kinesiophobia in patients with chronic low back pain.


Eligibility criteria:
inclusion criteria: * volunteered to participate in the study. * patients with 18-65 years * had low back pain for at least 6 months, * reported pain severity of 5 or greater according to the numeric pain rating scale * used pregabalin and gabapentin derivatives, exclusion criteria: * previous spine or lower extremity surgery * severe osteoporosis * spondyloarthropathy * spondylolisthesis * lumbar stenosis * systemic inflammatory diseases